A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus–associated lymphoid malignancies

Malignancies associated with latent Epstein-Barr virus (EBV) are resistant to nucleoside-type antiviral agents because the viral enzyme target of these antiviral drugs, thymidine kinase (TK), is not expressed. Short-chain fatty acids, such as butyrate, induce EBV-TK expression in latently infected B...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Perrine, Susan P., Hermine, Olivier, Small, Trudy, Suarez, Felipe, O'Reilly, Richard, Boulad, Farid, Fingeroth, Joyce, Askin, Melissa, Levy, Arthur, Mentzer, Steven J., Di Nicola, Massimo, Gianni, Alessandro M., Klein, Christoph, Horwitz, Steven, Faller, Douglas V.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2007
Materias:
Neoplasia
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC1852196/
https://ncbi.nlm.nih.gov/pubmed/17119113
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2006-01-024703
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares